Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004359|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
OBJECTIVES: I. Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in patients with epidermolysis bullosa acquisita.
II. Investigate the effect of ECP on lymphocyte activity.
|Condition or disease||Intervention/treatment||Phase|
|Epidermolysis Bullosa Acquisita||Drug: methoxsalen||Phase 2|
PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then returned to the patient. The process is repeated on 2 successive days.
Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Study Start Date :||February 1996|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004359
|Study Chair:||Kenneth B. Gordon||Northwestern University|